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Background: Tumour-derived extracellular vesicles (EVs) play a role in tumour progression; however, the
spectrum of molecular mechanisms regulating EV secretion and cargo selection remain to be fully elucidated.
We have reported that cavin-1 expression in prostate cancer PC3 cells reduced the abundance of a subset of EV
proteins, concomitant with reduced xenograft tumour growth and metastasis.
Methods: We examined the functional outcomes and mechanisms of cavin-1 expression on PC3-derived EVs
(PC3-EVs).
Results: PC3-EVs were internalized by osteoclast precursor RAW264.7 cells and primary human osteoblasts
(hOBs) in vitro, stimulating osteoclastogenesis 37-fold and hOB proliferation 1.5-fold, respectively. Strikingly,
EVs derived from cavin-1-expressing PC3 cells (cavin-1-PC3-EVs) failed to induce multinucleate osteoblasts or
hOB proliferation. Cavin-1 was not detected in EVs, indicating an indirect mechanism of action. EV
morphology, size and quantity were also not affected by cavin-1 expression, suggesting that cavin-1 modulated
EV cargo recruitment rather than release. While cavin-1-EVs had no osteoclastogenic function, they were
internalized by RAW264.7 cells but at a reduced efficiency compared to control EVs. EV surface proteins are
requiredforinternalizationofPC3-EVsbyRAW264.7cells,asproteinaseKtreatmentabolisheduptakeofboth
control and cavin-1-PC3-EVs. Removal of sialic acid modifications by neuraminidase treatment increased the
amount of control PC3-EVs internalized by RAW264.7 cells, without affecting cavin-1-PC3-EVs. This suggests
that cavin-1 expression altered the glycosylation modifications on PC3-EV surface. Finally, cavin-1 expression
did not affect EV in vivo tissue targeting as both control and cavin-1-PC3-EVs were predominantly retained in
the lung and bone 24 hours after injection into mice.
Discussion: Taken together, our results reveal a novel pathway for EV cargo sorting, and highlight the
potential of utilizing cavin-1-mediated pathways to attenuate metastatic prostate cancer.
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O
necommontraitofadvancedprostatecancerisits
propensity to metastasize to the bone with 80%
of patients with metastatic disease possessing
bone lesions (1). While portending a poor prognosis
with a 5-year survival rate of only 30% compared to 100%
for localized disease, bone metastasis also results in

Journal of Extracellular Vesicles 2014. # 2014 Kerry L. Inder et al. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
1
Citation: Journal of Extracellular Vesicles 2014, 3: 23784 - http://dx.doi.org/10.3402/jev.v3.23784
(page number not for citation purpose)substantial morbidities, including bone pain, fractures
and hypercalcaemia (2). The processes that underpin
prostate cancer metastasis remain undefined but it is
clear that a multifaceted interplay between tumour cells
and the bone microenvironment is instrumental in the
development of the metastatic niche (1,2).
Whiletheimportanceofsecretedmoleculesfromcancer
cells into the tumour microenvironment has been exten-
sivelystudied,anemergingfieldnowfocusesonthecontri-
butions of extracellular vesicles (EVs) secreted by tumour
cells. EVs are small membrane-bound vesicles that range
from 30 nm to 1 mm in size with larger vesicles originating
from the cell surface (microvesicles/ectosomes) and those
on the smaller side being derived from either the plasma
membrane or the endosomal system (exosomes). EVs en-
case a spectrum of biologically active proteins, mRNA,
miRNA,DNA andlipids, thuspropagating the horizontal
transferoftheircargoacrossbothshortandlongdistances
(3 7). Functional studies indicate that EVs may influence
tumour progression and metastasis, with investigations
showing tumour-derived EVs are capable of inducing
angiogenesis (8), increasing migration and proliferation
(9,10), immune suppression (11,12) and establishment of
the pre-metastatic niche (13). Both normal and malignant
prostate epithelial cells secrete EVs (also referred to as
prostasomes). While prostate-derived EVs have physiolo-
gical roles related to fertility, elevated levels have been
observed in blood samples from men with prostate cancer
compared to healthy controls (14). Interestingly, pro-
teomic analysis of a prostasome fraction prepared from
tissues of prostate cancer vertebral metastases revealed
proteins potentially involved with tumour angiogenesis
(15). Recent studies further indicate a role for prostate
cancer EVs in stromal remodelling, tumour angiogenesis
(16)andtransformationofadipose-derivedstemcells(17).
Therefore, identification of molecular pathways involved
in thevesicular secretion of metastasis-inducing molecules
may provide new therapeutic targets for treatment of
cancer metastasis.
Here we report a novel pathway regulating EV cargo
sorting without altering bulk vesicle release. The study
stems from our initial observation that expression of
cavin-1 (also known as polymerase I and transcript release
factor; PTRF) induced the selective reduction of tumour-
associated growth factors and cytokines, including IL-6
and TGF-b2 in EVs derived from the advanced prostate
cancer cell line PC3 (18). Importantly, we recently dem-
onstrated the in vivo relevance of cavin-1 in tumour
suppression using an orthotopic xenograft mouse model
(19,20). Here, we demonstrate that cavin-1 expression in
PC3 cells reduced the biological activity of PC3-EVs on
bone cells in vitro, with no qualitative alteration in in vivo
tissue distribution. We performed detailed analysis of EV
uptake kinetics and evaluated the effect of cavin-1 expres-
sion on EV secretion and morphology. Surprisingly, while
cavin-1 expression reduced the level of a subset of EV
proteins, there was no significant difference in total EV
proteinreleasedpercell,orbulkmorphology.Theseresults
suggest that cavin-1 expression alters EV cargo selection
rather than EVrelease.
Methods
Reagents and antibodies
Reagents and antibodies used were provided by the fol-
lowing sources:Roswell Park Memorial Institute (RPMI)-
1640 medium, a-Minimum Essential Medium (a-MEM),
Dulbecco’s Modified Eagle Medium (DMEM), L-gluta-
mine, HEPES, Geneticin (G418), penicillin streptomycin,
ProLong Gold Antifade and trypsin were from Life Tech-
nologies (Grand Island, NY, USA). Fetal bovine serum
(FBS) was from Thermo Scientific (Mordialloc, Vic, AUS).
Fast Red Violet LB Salt, napthol AS-MX Phosphate,
PKH2 and CellVue Claret Far Red Fluorescent Cell
Linker Kits were from Sigma-Aldrich (Saint Louis, MO,
USA). Antibodies against calnexin and caveolin-1 were
from BD Transduction Laboratories (Franklin Lakes, NJ,
USA),cofilinandEphA2fromCellSignallingTechnology
(Franklin Lakes, NJ, USA), cavin-1 from ProteinTech
(Chicago, IL, USA), a-tubulin and 4F2 from Sigma-
Aldrich (Saint Louis, MO, USA), and CD63 from Devel-
opmentalStudiesHybridomaBank(IowaCity,IA,USA).
Cell culture
Two independent sets of PC3 cell lines were used for
collection of EVs during this study, with similar results. As
describedin(21),PC3cellsstablyexpressingeitherGFPor
GFP-cavin-1 were grown in RPMI-1640 with 5% FBS, 1%
L-glutamine and 0.1 mg/mL of G418. Lentiviruswas used
to generate a set of PC3-luciferase cell lines expressing
GFPonlyorGFPandcavin-1underabicistronicpromoter
(19). Flow cytometry was used to generate a pooled
population of medium fluorescence intensity. These cells
were used for the in vivo animal model in (19). Primary
human osteoblasts (hOB) were obtained from patients
after knee replacement surgery as previously described
(22). hOB were maintained in a-MEM containing 10%
FBS, 1% penicillin-streptomycin and passages 1 5 only
were used. RAW264.7 cells were cultured in DMEM with
10% FBS, 1% HEPES, 1% L-glutamine and 1% sodium
pyruvate.
EV isolation and labelling
EVs were isolated from PC3 cells as previously described
(18). Between four and six 15-cm dishes of cells grown
to 70% confluency were washed 3 times with phosphate-
buffered saline (PBS) to remove any trace of serum and
then incubated for 24 hours in serum-free media. Cell
culture supernatant was then collected and cell debris
removed by centrifugation at 800 g for 5 min at 48C
and then 5,000 g for 10 min at 48C to remove any
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was concentrated through an Amicon 10 kDa cutoff
spin column (Millipore) and protein concentration was
measured using Bradford assay (Biorad). Isolation of EVs
from cleared supernatant was performed by ultracentri-
fugationofthesupernatantat 100,000g,2 hours,48C.The
supernatant was transferred to a new tube and stored on
ice, and the EV pellets were washed with ice cold PBS and
again pelleted at 100,000 g, 2 hours, 48C. Pellets were
re-suspended in PBS for functional assays and used
immediately or store at  808C.
Where indicated, EVs were fluorescently labelled with
PKH2orCellVueClaretFarRedFluorescenceCellLinker
Kit according to the manufacturer’s protocol. Briefly, EVs
(10 20 mg pellets) were incubated with PKH2 or CellVue
(500 mL 0.2 mM) for 5 min at room temperature. Labelled
EVs were diluted in 500 mL 1% BSA, and then pelleted
at 100,000 g, 2 hours, 48C, washed with 1 mL PBS to
remove excess dye, re-suspended again in 1 mL PBS and
then pelleted again at 100,000 g, 2 hours, 48C before final
re-suspension in 50 mL PBS. In initial experiments, a con-
trol tube containing no EV (dye alone) was performed to
ensure lack of fluorescence in the absence of EV. Similar
proteinconcentrationsobtainedbeforeandafterEVlabel-
ling (Bradford assay) confirmed that labelled EVs were
not contaminatedwith BSAused to stop dye reaction. For
all subsequent functional experiments, protein estimation
was only performed before labelling EVs.
Proteinase K and neuraminidase treatment
Where indicated EVswere incubatedwith 0.2 mg/mL pro-
teinase K (Roche Applied Science, Laval, QC, Canada)
for 30 min at 378C to digest the EV surface proteins. For
deglycosylation, prostasomeswere re-suspended in 50 mM
sodium citrate (pH 6.0) and treatedwith 100 units of neur-
aminidase (New England Biolabs, Ipswich, MA, USA)
per mg for 2 hours at 378C. Following incubation with
ProK/NRM prostasomes were washed in PBS and then
re-suspended in PBS.
hOB proliferation assay
hOBs were plated in 96 well plates at a density of 5,000
cells/well in a-MEM containing 10% FBS. Cells were left
to adhere overnight, after which they were treated with
either 1% BSA (control), 5 mg GFP-PC3-EV or 5 mg
cavin-1-PC3-EV (final concentration of 0.05 mg/ml) re-
suspended in 1% BSA for 48 hours. After 48 hours incu-
bation, proliferation was quantified using the AlamarBlue
cell viability assay (Invitrogen) according to manufacturer’s
instructions. Six replicateswere performed for 3 biological
experiments.
RAW264.7 differentiation and TRAP staining
RAW264.7 cells were seeded in 48 well plates at a density
of 2,000 cells/cm
2 (Day 0). The following day (Day 1),
cells were treated with either PBS, 50 ng/mL RANKL or
20 mg/mL PC3-EVs. Conditions and growth media were
replaced on Day 4. On Day 7, cells were fixed with 4%
PFA and stained for tartrate resistant acid phosphatase
(TRAP) (50 mM sodium acetate, 40 mM sodium potas-
sium tartrate, 10% napthol AS-MX phosphate, 1% N,
N-dimethylformamide, 40% Fast Red Violet LB salt,
dH2O). Osteoclasts were identified as TRAP positive,
multinucleated cells (3 or more nuclei). Osteoclasts were
counted manually using an inverted light microscope
visualised at 200  magnification. Four replicates were
performed per condition with 6 independent experiments
performed.
EV uptake
hOBs and RAW264.7 cells were grown in DMEM
containing 10% FBS on glass coverslips in 6 well dishes
until they reached 60% confluency. Each well was in-
cubated with 10 mg of labelled EVs (final concentration
5 mg/mL) or the equivalent amount of dye in 1% BSA
(to control for background fluorescence) at 378C for the
indicated time points. Coverslipswerewashed 3 timeswith
cold PBS to remove unbound EVs, and then fixed for
30 min in 4% PFA. Representative images were taken for
each time point using a Zeiss Meta 510 confocal micro-
scope. Uptake efficiency over time was determined by
measuring the total cellular fluorescence over time (using
ImageJ), adjusting for background. The mean fluores-
cence of hOB ( 20 30 cells per time point) and
RAW264.7 ( 40 cells) was calculated across 3 indepen-
dent experiments. The value for each time period is
represented as a percentage of the peak in fluorescence.
Immunofluorescence
After fixation with 4% PFA, cells were permeabilized and
blocked using 0.1% Triton X-100, 1% BSA in PBS for
30 min at room temperature. Cells were stained with a-
tubulin antibody for 1 hour, washed 3 times in PBS, and
incubated with Alexa Fluor 488-conjugated goat anti-
mouse antibody (Life technologies) for 1 hour. Staining
for actin ring formation was performed using 1-hour
incubation with Texas Red conjugated phalloidin (Life
Technologies),followedbyDAPI.Coverslipsweremounted
using ProLong Gold Antifade reagent and visualized
using a Zeiss Meta 510 confocal microscope.
Western blotting
Whole cell lysates (WCLs) were collected by pelleting
cells from a 15 cm dish and treating with lysis buffer
containing 150 mM NaCl, 20 mM Tris pH 7.5, 0.5%
TritonX-100, 0.5 mM sodium vanadate, 10 mM sodium
fluoride, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluor-
ide hydrochloride, protease inhibitor cocktail (1 mg/mL
aprotinin, 1 mg/mL antipain, 1 mg/mL pepstatin A, 1 mg/
mL leupeptin and 500 mM benzamidine). EV or WCL
protein was measured using Bradford assay (BioRad) and
10 mg was resolved on SDS-PAGE gel and transferred
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Membranes were blocked using 5% milk powder in Tris
buffered saline (pH 7.5) containing 0.1% Tween- 20 and
incubated with the primary antibody for 2 hours at room
temperature. After washing, secondary antibodies conju-
gated to horseradish peroxidase were applied for 2 hours
at room temperature. Blots were developed using Super-
Signal West Pico Chemiluminescent Substrate and im-
aged using film (Fujifilm).
RNA isolation and miRNA qPCR
Total RNA was isolated from whole cells or from EVs
(70 mg protein) using mirVana RNA isolation kit (Ambion)
following the manufacturer’s instructions. 1 mg of DNase
I (Ambion) treated and polyadenylated (NEB) RNA was
used for cDNA synthesis using SuperScript III (Life
Technologies). Real-time qPCR was performed using
SensiFAST SYBR NoROX Kit (Bioline) in a Rotor-
Gene 3000 real-time rotary analyser (Corbett Life
Science). The relative level of miR-148a and miR125a
was calculated from the relative signal by normaliza-
tion to the signal for miR-107_2, which showed minimal
variation between GFP-PC3-EVs and cavin-1-PC3-EVs.
Primers for miR-148a and miR-107_2 were purchased
from Qiagen and the primer for miR-125a was designed
manually using the sequence 5?-TCCCTGAGACCCTT-
TAACCTGTGA-3?.
Electron microscopy
Negative staining and electron microscopy (EM) was
performed as previously described (23). Briefly, Immuno-
EM was performed as follows; EVs were adhered to
grids, cross-linked (4% PFA) then quenched with glycine
(20 mM). Grids were blocked (0.2% BSA, 0.2% fish skin
gelatin) for 10 min then labelled with primary antibody
for 30 min followed by 3 PBS washes. Grids were then
incubated on 10 nm protein A gold for 30 min, washed in
PBS then water. Grids were then stained and mounted
with methyl cellulose (2%) and uranyl acetate (0.4%).
Electron micrographs were captured on a JEOL1011
electron microscope at 80 kV fitted with a Morada soft
imaging system.
Flow cytometry
RAW264.7 cells were seeded overnight at 4 10
5 cells
per tube. EVs were labelled using the PKH2 or CellVue
Claret fluorescent dye. Labelled EVs (20 mg) were in-
cubated with RAW267.4 cells for 2 hours at 378C. Cells
were washed 3 times in cold PBS before being fixed in
3% PFA. Flow cytometry analysis was carried out using
a FACSCanto (BD Biosciences). The background mean
fluorescence from RAW264.7 cells not incubated with
fluorescent EVs was subtracted from the mean fluores-
cence intensity of the experimental conditions.
In vivo EV distribution
The animal experiments were approved by the University
of Queensland Animal Ethics Committee (UQDI/326/10/
AICR and UQDI/076/14/NHMRC). 30 mg GFP-PC3-
EVs labelled with PKH2 fluorescent dye and 30 mg cavin-
1-PC3-EV labelled with CellVue Claret fluorescent dye
were mixed in 150 mL of PBS. 50 mL of EV mix (final
amount 10 mg GFP-PC3-EVs and 10 mg cavin-1-PC3-EV)
was injected into the tail vein of 8-week-old male NOD/
SCID mice. Control mice were injected with 50 mLo f
PBS. After 24 hours, the bone marrow was harvested
from the long bones (femur and tibia) and disrupted into
cell suspensions in PBS. The cell suspension was smeared
on a glass slide and mounted in DAPI-containing
Vectashield mounting media and EV uptake was imaged
using a Zeiss Meta 510 confocal microscope. After 24
hours, the lung, heart, spleen, liver, kidney, thymus, brain
and prostate were excised. For each solid organ, small
pieces were removed and fixed in 4% PFA for 16 hours.
The remaining tissue was embedded in OCT (Optimum
Cutting Temperature) compound and frozen at  808C.
All other PFA fixed tissue pieces were imaged by a
LaVision Biotek mupltiphoton system with a turnable
titanium Sapphire laser. Tissues that were posi-
tive for EV uptake by multi-photon microscopy were
then confirmed by confocal microscopy using 12 mm
cryosections of the corresponding OCT frozen tissues.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 software. Where applicable, resultswere compared using
either a 2-tailed paired Student’s t-test, or a one-way ana-
lysis of variance with Bonferroni’s post-test for multiple
comparisons. Data are expressed as the mean9SEM,
with statistical significance defined as pB0.05.
Results
Cavin-1 altered abundance of EV proteins and
miR-148a with no effect on total cellular levels
We previously demonstrated that cavin-1 expression
suppressed PC3 tumour growth and metastasis in vivo
(19) concomitant with changes to PC3-EVproteome (18).
To characterize the functional consequences correlating
with cavin-1 induced EV content changes, we focused our
attention on bone cells because PC3 cells were derived
from abone-metastatic prostate cancer (24) and PC3-con-
ditioned media and EV have been reported to induce
osteoclastogenesis in vitro (25 27). First, we examined
if any of the PC3-EV proteins have established links to
bone-associated functions or bone metastasis (Table I).
Cavin-1 reduced the levels of 12 PC3-EV proteins that in-
cluded bone matrix proteins collagen VI and fibronectin,
drivers of osteoclastogenesis IL-6 and TGF-b,a sw e l la s
the osteoblast inhibitor noggin (28). However, IGFBP-2
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minogen activator (osteoclast mediated bone degrada-
tion) (30) were significantly increased in cavin-1-PC3-EVs.
In addition, membrane proteins 4F2 heavy chain antigen
(also known as solute carrier family 3 member 2, SLC3A2
or CD98) and EphA2 were reduced in cavin-1-PC3-EV.
Both have documented roles in osteoclastogenesis (31,32).
Toconfirmthecavin-1effectontheEV-mediatedrelease
of these proteins, and to determine whether cavin-1
affected total protein expression or only the release as we
previously reported for cytokines (18), we compared the
levelsof selected proteins in the WCL and EVs from GFP-
PC3 and cavin-1-PC3 cells by immunoblotting. As shown
in Fig. 1A, caveolin-1 WCL and EV levelswere not altered
by cavin-1 expression. Cavin-1 itself was not detected in
EVs indicating its effects are indirect (Fig. 1A). Calnexin
was used as an intracellular membrane marker, which was
not detected in EVs (Fig. 1A). We also probed for cofilin
and CD63 as known exosome cargo and marker protein,
respectively. Interestingly, both cofilin and CD63 were
increased in the EVs from cavin-1-PC3 cells compared to
GFP-PC3cells(Fig.1A).Additionally,CD63totalcellular
levels were also elevated in cavin-1-PC3 cells (Fig. 1A),
suggesting potential increase in multi-vesicular body
formation. In contrast, cavin-1 expression reduced the
abundanceof4F2andEphA2inEVswithoutaffectingtotal
cellular levels (WCL, Fig. 1A) similar to our previous
report for cytokines and proteases (18). This suggests that
cavin-1 did not cause a decrease of key bone remodelling
molecules on the cellular level but instead altered their
secretion through EVs.
Recent studies show that EVs mediate the transfer
of functional microRNA (miRNA) (4,6), and miRNA
changes are implicated in osteolytic bone metastasis (33).
Therefore, we were interested to investigate if, in addition
to proteins, cavin-1 expression altered miRNA secretion
via EVs. Based on a review of recent literature, we chose
to measure 2 miRNA species, miRNA-148a and miR-
125a. Over expression of miR-148a was recently reported
to induce osteoclastogenesis and the reverse was observed
when miR-148awas inhibited (34). In contrast, miR-125a
was reported to be decreased during osteoclastogenesis
(34). qPCR performed revealed that PC3-EV miRNA-
148a levels were significantly reduced by 3.6790.014-
fold (p  0.02) upon cavin-1 expression without altering
total cellular miR-148a levels (Fig. 1B). In contrast, no
significant difference was found for miR-125a in either
EVs or total cell (Fig. 1C). These results suggest that
cavin-1 expression can selectively modulate EV-mediated
transfer of miRNA.
Table I. Effect of cavin-1 expression on proteins in PC3 EVs with reported roles in bone metastasis
Accession Protein name Mean ratio (cavin-1:GFP) No. of Obs p
Decreased in cavin-1 EVs
P05231 Interleukin-6 0.1011 28 0.0063
Q13253 Noggin 0.1575 2 0.00414
P12110 Collagen alpha-2(VI) chain 0.262 3 0.00618
P08476 Inhibin beta A chain 0.2396 30 0.00683
P17936 Insulin-like growth factor-binding protein 3 0.3655 2 0.03129
P12109 Collagen alpha-1(VI) chain 0.4159 62 0.01493
P08195 4F2 cell-surface antigen heavy chain 0.4424 14 0.01487
P00749 Urokinase-type plasminogen activator 0.4494 139 0.03151
P29317 Ephrin type-A receptor 2 0.527 11 0.02467
P04080 Cystatin-B 0.5346 27 0.0169
P02751 Fibronectin 0.567 4 0.14112
P61812 Transforming growth factor beta-2 0.5858 55 0.01978
Increased in cavin-1 EVs
P18065 Insulin-like growth factor-binding protein 2 3.9048 4 0.00605
P00750 Tissue-type plasminogen activator 2.0035 6 0.03213
No change in cavin-1 EVs
Q15828 Cystatin-M 0.63017 6 0.23465
O94907 Dickkopf-related protein 1 0.73475 8 0.58905
Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 0.79309 22 0.80976
P01034 Cystatin-C 0.82386 22 0.87766
O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 1.02675 4 0.97971
EVs were collected from stable isotopically labelled cells (SILAC) and analysed by LC MS/MS (see (18) for details). SILAC ratios
(cavin-1:GFP) provide an accurate relative quantitation of the 2 samples and p-value indicates significance. Primary data were published
as Supplementary table in (18).
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The pathology of bone metastasis is a result of aberrant
bone remodelling mediated primarily by 2 cell types,
bone-forming osteoblasts and bone-resorbing osteoclasts.
Osteoclasts are giant multinucleated cells differentiated
from myeloid precursorcellswithin thebone marrow. Two
essential molecules, receptor activator of NF-kB ligand
(RANKL) and macrophage colony stimulating factor
(M-CSF) stimulate canonical osteoclast differentiation
while osteoprotegerin (OPG) actsas a RANKL decoy (35).
Prostate cancer cells are known to secrete factors that dis-
rupt the RANKL/OPG regulatory axis and osteoclast
activity(36),however,therelativecontributionsofsecreted
soluble factors (SF) versus EV have not been assessed.
To establish the in vitro function of EVs on bone cells,
we selected murine RAW264.7 pre-osteoclast cells, and
human primary osteoblast cells, and assayed the relative
abilities of total secretome, and the 2 secretome sub-
fractions (SF and EVs) to induce osteoclastogenesis and
osteoblast proliferation. Similar toprevious studies (25,26),
differentiation of RAW264.7 cells to osteoclasts was mea-
suredbyenumeratingmulti-nucleatedTRAP-positivecells.
Optimal cell seeding and secretome treatment conditions
were established in preliminary studies (data not shown).
Secretome and the sub-fractions were normalized by
protein amount. RANKL was used as a positive control
(Fig. 2). As expected, total secretome and PC3-EVs in-
duced osteoclastogenesis of RAW264.7 cells compared to
the PBS negative control (Fig. 2A, 2B). Interestingly, SF
alone was unable to induce osteoclastogenesis, indicating
requirement for EV components (Fig. 2B). In agreement,
enriched EV more effectively induced osteoclastogenesis
compared to total secretome (Fig. 2B). Formation of
an F-actin ring is required for effective osteoclast bone
resorption (37), and as shown in Fig. 2C, similar pro-
portion of F-actin ring-positive osteoclasts were observed
in both PC3-EVs and RANKL-treated conditions, sug-
gesting that PC3-EVs are capable of inducing full osteo-
clastogenesis. In comparison to GFP-PC3-EV, total
secretome from cavin-1-PC3 cells showed  2-fold less
Fig. 1. Cavin-1 altered EV proteins and EV miR-148a with no effect on total cellular levels. (A) EVs and whole cell lysates (WCL) were
collected from GFP-PC3 and cavin-1-PC3 cells and analysed by Western blot with the indicated antibodies. EV preparations were
free from ER protein calnexin. Equal loading was shown by Coomassie staining. Images are representative of 3 biological replicates.
Raw images of the western blots are available in ﬁgures in Supplementary ﬁle. (B) Cavin-1 alters the miRNA content of EVs. Real-time
qPCR was performed on cDNA synthesized from equal amounts of RNA extracted from GFP-PC3-EVs and cavin-1-PC3-EVs or
total cell lysates. Bar graphs show the mean relative expression9SEM of miR-148a was signiﬁcantly decreased in cavin-1-PC3-EVs
compared to GFP-PC3-EVs (p 0.02, n 3) but expression of miR-148a was unaffected in cells. (C) In contrast, miR-125a was not
signiﬁcantly different between GFP-PC3-EVs and cavin-1-PC3-EVs (n 3).
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PC3-EVs induced TRAP expression (Fig. 2A) but were
unable to induce fusion to multi-nucleated cells (Fig. 2A,
2B). This suggests that soluble secreted factors in cavin-1-
PC3 secretome are required for fusogenic activity during
osteoclastogenesis by PC3-EVs.
With the exception of cavin-1-EV, secretome treatments
significantly increased the proliferation of hOBs com-
pared to PBS control (Fig. 2D). For total secretome and
SF, cavin-1 expression significantly reduced the response
compared to the respective GFP controls (Fig. 2D). This
data suggests that cavin-1 expression reduced the secre-
tion of both soluble and EV components which stimulate
hOB proliferation. Interestingly, the magnitude of PC3-
EV-induced osteoblast proliferation was only 1.43 fold,
compared with a 37-fold increase in osteoclastogensis
uponincubationwithPC3-EV(Fig.2C,2D).Theseresults
may explain the predominant osteolytic lesions pro-
duced by PC3 cells (38 40), when osteoblastic and mixed
osteoblastic/osteolytic bone lesions are common in pros-
tate cancers (41).
Cavin-1 does not affect bulk EV release
WenextaskedifthechangesinEVmoleculesuponcavin-1
expression are due to a block in the secretion of a par-
ticularsubsetofEVs.Tothisend,themorphologyandsize
of the EVs released from GFP-PC3 and cavin-1-PC3 ex-
pressing cellswas examined using EM (Fig. 3A). Vesicular
structureswithaverymixedrangeofdiametersbetween30
nm and 500 nm, were observed in EV preparations from
GFP-PC3 and cavin-1-PC3 cells. Few large oncosomes
( 1 mM) recently reported to be secreted by PC3 cells
(42,43) were observed. This may be due to differences in
EV preparation methods. There was no significant differ-
ence in the average diameter of GFP-PC3-EVs and cavin-
1-PC3-EVs with mean diameters of 91.54 nm90.61 nm
Fig. 2. PC3-EV activity is attenuated by cavin-1 expression. (A) RAW264.7 cell differentiation to osteoclast was measured by
the number of TRAP-positive (pink) multi-nucleated cells (3 or more nuclei) after treatment for 6 days, as detailed in Methods.
Representative microscopic images show negative control (PBS), positive control (RANKL) and effects of GFP-PC3-EV and cavin-1-
PC3 EV. Bar 50 mm. (B) RAW264.7 cells were treated with 20 mg/mL of total secretome (Sec.), soluble secretome fraction (SF), EV,
or control (PBS or 50 ng/mL RANKL). The number of TRAP-positive multinucleated cells was quantiﬁed over 4 independent
experiments, each with triplicate wells. Signiﬁcance from PBS control is indicated by ** pB0.005, *** pB0.0005, **** pB0.00005. (C)
Actin rings in osteoclasts were determined by staining with Texas Red conjugated phalloidin to stain for actin (red), and DAPI to stain
for nuclei (blue). There was no signiﬁcant difference between RANKL and GFP-PC3-EV-induced osteoclasts (n 3). Bar 20 mm. (D)
Primary hOB cells (3 independent lines) were treated with 5 mg of total secretome (Sec.), soluble secretome fraction (SF), EV, or control
(PBS control) for 48 hours. Proliferation was measured by AlamarBlue assay, with 4 replicates per experiment. Signiﬁcance from PBS
control is indicated by *B0.05, ** pB0.005, *** pB0.0005. NS, not signiﬁcant.
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ascertain whether a subset of EVs of a certain size was
affectedbycavin-1weanalysedthesizedistributionofEVs
using increments of 10 nm diameter (Fig. 3B). Overall the
distribution was very similar between GFP-PC3-EV and
cavin-1-PC3-EV with a small but statistically significant
decrease in EVs 70 80 nm in diameter observed. To exa-
mine if this particular subpopulation of EVs may be
enriched in the bone associated proteins altered by cavin-1
(Table I), we performed immuno-EM for the membrane
protein 4F2 as a marker. Given 4F2 is a single pass mem-
braneproteinwereasoneditislikelytobeonthesurfaceof
EVs, and therefore a candidate for immuno-labelling of
EVs. Immuno-EM confirmed 4F2 as an EV surface pro-
tein(Fig.3D),andanalysisofthesizedistributionrevealed
that 4F2 labelled EVs of various sizes, ranging from 50 
280 nm diameter (Fig. 3E). Whilst 4F2 did label vesicles
ranging from 70 80 nm, this represented only 14% of the
total 4F2 labelled EVs and is unlikely to account for the
significant reduction observed in cavin-1-PC3-EVs. Con-
sistently, GFP-PC3 and cavin-1-PC3 cells secreted the
same levels of EVs when measured as EV protein
concentrationrelativetocellnumberortototalcellprotein
level(Fig. 3F,G). Given thelackofchangesin secretedEV
Fig. 3. Cavin-1 expression does not change the size or quantity of EVs released. (A) EVs (indicated by arrows) isolated from GFP-PC3
and cavin-1-PC3 cells were inspected by electron microscopy for morphological differences. Scale bar 1000 nm. (B) The diameter of
GFP-PC3-EVs (n 916) and cavin-1-PC3-EVs (n 965) was quantitated using ImageJ and represented as a histogram (Each bar
indicates the percentage of EVs up to mean diameter9SEM, that is, 40 nm means between 30 40 nm) and (C) the average EV
diameter9SEM plotted as a bar graph. No signiﬁcance difference was observed in the average diameter between GFP-PC3-EVs and
cavin-1-PC3-EVs. (D) Representative images of 4F2 immunolabelled EVs showing 4F2 labels a range of different sized EVs. Scale
bar 500 nm. (E) The mean diameter9SEM of 4F2 labelled EVs (n 107) were quantitated using ImageJ and represented as a
histogram. Each bar indicates up to diameter, i.e. 40 nm means 30 40 nm. The protein concentration of GFP-PC3-EVs and cavin-1-
PC3-EVs was quantitated using Bradford assay and normalized to (F) total cell number and (G) mg per whole cell lysate (WCL) protein
estimation from the cells they were derived. No signiﬁcant differences were observed (mean9SEM, n 3).
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cavin-1 targets the release of low abundant functional
proteins without affecting the overall release of EVs.
Cavin-1 reduces EV uptake through surface protein
expression
Having established that cavin-1 expression does not
alter PC3-EV release, we next investigated if PC3-EV
internalization into the target cell is reduced. To establish
experimental parameters for the quantitative analysis of
PC3-EV uptake, we first characterized the time course
of PC3-EV internalization to hOB and RAW264.7 cells
invitro. PC3-EVswerefluorescently labelledwith CellVue/
Far Red dye and incubated with hOB or RAW264.7 cells
for 0, 5, 15, 30 minutes and 1, 2, 20 hours. PC3-EVs that
were not internalized or bound to the surface of cells
were washed away using PBS. Cells were then fixed using
4% PFA, stained with a-tubulin antibody and observed
by confocal microscopy (Fig. 4A). Quantitation was per-
formed using ImageJ to measure total cellular fluores-
cence, with the results expressed as delta fluorescence
intensity by adjusting for background fluorescence (cells
without EV incubation). Rapid internalization as early
as 5 minutes was observed in both cell types (Fig. 4B).
However, uptake was faster in hOB cells with internaliza-
tion peaking at 30 minutes compared to RAW264.7 cells
that peaked at 2 hours (Fig. 4B).
For quantitative comparison of PC3-EV internaliza-
tion, equal quantities of GFP-PC3-EV and cavin-1-PC3-
EVs were labelled with the lipophilic dye PKH2 and
added to RAW264.7 macrophage cultures for 2 hours.
Cells were washed extensively and cell-associated fluor-
escence was determined by flow cytometry. These assays
provided 2 quantitative measures of EV uptake: percen-
tage of cells which internalized fluorescent EVs, and
the relative amount of EVs internalized by those cells
(delta mean fluorescence intensity). Fluorescence was
detected in 94.792.2% of RAW264.7 cells after incuba-
tion with GFP-PC3-EVs (Fig. 4C). In comparison, there
was a significantly lower percentage of fluorescent cells
upon addition of cavin-1-PC3-EVs (75.297.5%). Similar
results were observed for delta mean fluorescence in-
tensity, but the difference was not statistically signifi-
cant (p 0.0815, Fig. 4D). These observations suggest
that cavin-1 expression attenuated PC3-EV uptake by
RAW264.7 cells, potentially by altering the molecular
components on the EV surface.
EV surface protein and glycans have been implicated
as determinants of EV uptake (44). To investigate the
involvement of these components, we utilized proteinase
K and neuraminidase to compromise surface protein and
sialic acid moieties. By both percentage of fluorescent
cells, and the delta mean fluorescence intensity, protei-
nase K treatment significantly impaired the uptake of
GFP-PC3-EVs and cavin-1-PC3-EVs into RAW264.7
cells (Fig. 4D), indicating a key role for surface proteins
in EV internalization. Interestingly, the residual uptake
after proteinase K treatment remained significantly dif-
ferent between GFP-PC3-EVs and cavin-1-PC3-EVs, sug-
gesting that non-protein determinants altered by cavin-1
expression also play a role in EV uptake.
Surprisingly, neuraminidase treatment differentially af-
fected the internalization of control and cavin-1-PC3-EVs.
Similar to proteinase K treatment, neuraminidase treat-
ment also attenuated the percentage of cells internalizing
control and cavin-1-PC3-EVs, maintaining the statistical
difference between the 2 EV types (Fig. 4D). However,
neuraminidase increased the delta mean fluorescence
intensity of internalized control PC-3 EVs without sig-
nificantly altering the delta mean fluorescent uptake
of cavin-1-PC3-EVs (Fig. 4E). Taken together, these data
suggest that removal of sialic acid from the EV surface
either increased the amount of EVs internalized (while
reducing the number of cells internalizing) or altered their
intracellular itinerary after uptake leading to intracellular
accumulation. The differential response to neuraminidase
treatment suggests that control and cavin-1-PC3-EVs con-
tain different surface sialic acid moieties.
PC3-EVs target to lung and bone marrow in vivo
Finally, we examined the in vivo tissue targeting of GFP-
PC3-EV and cavin-1-PC3-EV. Equal amount of fluores-
cently labelled GFP-PC3-EV (PKH2 label, green) and
cavin-1-PC3-EV (CellVue/Far Red label, red) were mixed
priortoinjectionintoNOD/SCIDmice.Controlmicewere
injectedwithPBSsincewehaveestablishedthatincubation
withthepelletofthefluorescence dyealonedidnotleadto
fluorescence retention in hOB and RAW264.7 cells invitro
(Fig. 4A). We chose a 24 hour time point to ensure
clearance of EVs from the blood and first pass organs
such as spleen and liver (45). Selected organs (bone
marrow, lung, liver, spleen, kidney, heart, thymus, brain,
prostateandseminalvesicle)werethenremoved,fixed,and
EV uptake observed by multiphoton microscopy. Similar
to EVs derived from melanoma cell line B16-F10 (13),
GFP-PC3-EVs predominately distributed to the bone
marrow and the lung, while no fluorescence was observed
in the liver, spleen, kidney, heart, thymus, brain, prostate
andseminalvesicle(Fig.5).Importantly,boneandlungare
common sites of prostate cancer metastasis in human
patients(41).Cavin-1-PC3-EVswerealsoobservedinbone
marrow and lung; however, due to the low number of EVs
remaining in tissue at the 24 hour time point, we were
unable to quantify any difference by confocal microscopy.
Similarly, the low level of fluorescence ofex vivo PC3-EVs
was not sufficient to be quantitatively measured by the
flow cytometry assay used with RAW264.7 cells in
the in vitro uptake experiment (Fig. 4C, D). Therefore,
while we detected similar tissue distribution between
GFP-PC3-EV and cavin-1-PC3-EV, we were unable to
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(page number not for citation purpose)Fig. 4. In vitro uptake of EVs. (A) PC3-EVs were labelled with CellVue Claret and incubated with RAW264.7 or hOB cells at 378Cf o r
the indicated times. Cells were co-stained with anti-tubulin antibody (green staining) and cell surface-bound or cell-internalized EVs
were visualized by the red stain. As a control, CellVue dye was centrifuged alongside EVs, and the pellet re-suspended and added to
cells (bottom panel). Representative confocal microscopy images are shown. Bar 10 mm. (B, C) EV uptake was quantiﬁed using
ImageJ to measure total cellular ﬂuorescence for 20 40 cells at each time point, across 3 independent experiments. The background
ﬂuorescence of cells incubated with CellVue dye subtracted to derive D Mean Fluorescence Intensity (9SEM). (D, E) 20 mg EVs from
GFP or cavin-1 PC3 cells were treated with proteinase K, neuraminidase or PBS control, labelled with PKH2 and then incubated with
4 10
5 RAW264.7 cells seeded in tubes at 378C for 2 hours. Uptake of ﬂuorescence was determined by ﬂow cytometry, with untreated
cells used for background ﬂuorescence levels. Data over 3 independent experiments were analysed for (D)% ﬂuorescent cells and (E) D
Mean Fluorescence Intensity9SEM.
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Discussion
Themolecular mechanismsregulatingtumour-derivedEV
release and subsequent function, particularly in metas-
tasis, are only beginning to be delineated. As a strategy
to inhibit cancer EV release, silencing of Rab27a was
very recently employed in prostate cancer DU145 cells
with significant reductions observed in the EV levels of
exosome marker proteins (TSG101, ALIX, LAMP2) and
the target cargo, TGF b1 (16). In contrast, our study re-
vealed a surprising mode of cavin-1 action on the recruit-
ment of functional EV cargo, rather than EV release.
Cavin-1 expression had no effect on EV release or in vivo
distribution, but attenuated EV uptake and EV-mediated
osteoclastogenesisandosteoblastproliferation,mostlikely
by affecting cargo recruitment.
Cavin-1 reduced the EV content of several proteins and
at least one miRNA with documented function in bone
remodelling (Table I, Fig. 2). IL-6, TGF-b, activin A and
IGFBP3 are normally present in the bone microenviron-
ment (46 49), and elevated circulating levels of IL-6,
TGF-b and activin A are associated with metastatic
prostate cancer (50 53). In this study, we also validated
the differential secretion of two EV membrane proteins,
EphA2 and 4F2 (Fig. 2A). The receptor tyrosine kinase
EphA2 is normally expressed on the surface of osteoclast
lineage cells and EphA2 and its ligand EphrinA2 have
been shown to facilitate the early stage of bone remodel-
ling by enhancing osteoclastogenesis and suppressing
osteoblast differentiation (31). PC3-EV uptake may be a
means to increase surface EphA2 levels beyond what is
normally expressed. EphA2 over expression in osteoclast
precursors was shown to dramatically increase differen-
tiation of osteoclasts (31). 4F2, on the contrary, has been
suggested to play a role in the fusion step of osteoclas-
togenesis (32). A reduction in 4F2 EV levels upon cavin-1
expression is consistent with our observation that cavin-
1-PC3-EVs caused TRAP expression but did not lead to
formation of multi-nucleated cells (Fig. 1A).
A recent quantitative proteomics analysis of secreted
proteins derived from cell lines with varying bone metas-
tasis attributes derived from different cancers, combined
withanalysisoflargeclinicalmetastasisdatasets,identified
7 genes (cystatins CST1, CST2 and CST3; plasminogen
activators PLAT and PLAU; and collagen functionality
proteinsPLOD2andCOL6A1)asnovelmediatorsofbone
metastasis (54). Interestingly, individual knockdown of
each gene did not block bone metastasis, however com-
bined over expression of genes from the same functional
group increased bone tumour burden (54). Notably, cavin-
1 expression affected each of these functional groups.
Cavin-1 significantly reduced the levels of cystatin-B in
EVs and similar to other cystatins, cystatin-B has been
reported to play a role in bone resorption (55). The bone
matrix proteins COL6A1 (collagen VI) and fibronectin
were also reduced in EVs after cavin-1 expression, and
PLOD2(procollagen-lysine, 2-oxoglutarate5-dioxygenase
2) was found as a component of EVs but not changed by
cavin-1. An important role for collagen VI in bone
metastasis is beginning to emerge with another recent
Fig. 5. EV in vivo distribution. PKH2 labelled GFP-PC3-EVs (green) and CellVue Claret labelled cavin-1-PC3-EVs (red) were injected
into the tail vein of NOD/SCID mice. Control mice were injected with PBS. After 24 hours, the bone marrow, lung, heart, spleen, liver
and kidney were excised, ﬁxed in 4% PFA and stained with DAPI (blue) to visualize nuclei. The arrow (GFP-PC3-EVs green) and the
bold arrow (cavin-1-PC3-EVs, red) indicate labelled EV uptake observed in bone marrow and lung. Bars 10 mm.
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collagen VI from metastatic compared to non-metastatic
lung cell lines (56). Finally, cavin-1 altered EV levels of
PLAU (urokinase-type plasminogen activator, uPA) and
PLAT (tissue-type plasminogen activator, tPA) albeit in
opposing directions. These serine proteases areinvolvedin
extracellular matrixdegradation and havebeen implicated
in osteoclast driven bone resorption (57). Like collagen
VI, over expression of uPA increased bone metastasis in a
prostate cancer mouse xenograft model (58).
In addition to proteins, our data suggest that cavin-1
also attenuated the sorting of miR-148a into EVs which
may contribute to the reduced osteoclastogenic activity
(34). A range of studies have implicated miR-148a in
breast cancer (59), gastric cancer (60), and metastasis
(61), however with seemingly contradictory results. In the
androgen-sensitive LNCaP prostate cancer cell line, an-
drogen induced miR-148a expression promoted cell pro-
liferation(62).Incontrast,ectopicexpressionofmiR-148a
in PC3 cells inhibited cell growth, migration and invasion
(63). It is possible that secreted EV miR-148a exerts dif-
ferent functions compared to the primary cancer cell
it was expressed in. Further studies on the differential
secretion of miRNA through EVs, and the role of cavin-1
in their regulation will be required.
Our data confirms previous reports that PC3 condi-
tioned media can induce osteoclastogenesis from murine
RAW264.7 cells (25 27), and further show that PC3-EVs
alone are sufficient to enhance osteoclastogenesis in vitro
(Fig. 1). However, cavin-1-PC3-EVswere unable to induce
full osteoclastogenesiswithout the soluble secretome (Fig.
1B), indicating the requirement of SF not released via
EVs. We also report for the first time that PC3 condi-
tioned media and EVs increase proliferation of primary
hOBs (Fig. 1D), although the magnitude of PC3-EV
osteoblastic activity was much lower than its osteoclasto-
genic activity. In contrast to our data, PC3 conditioned
media has been reported to suppress primary murine
osteoblast proliferation (64,65). The discrepancy may be
due to the use of human versus murine osteoblasts.
Our detailed internalization experiments revealed an
impairment of cavin-1-PC3-EVs uptake to RAW264.7
cells compared to control PC3-EVs (Fig. 4). However, EV
surface determinants required for tissue-specific targeting
and retention are not severely disrupted in cavin-1-PC3-
EVs as we observed both EV types in lung and bone after
injection into NOD/SCID mice (Fig. 5).
A number of mechanisms including phagocytosis,
macropinocytosis, and clathrin-dependent endocytosis
have been implicated in EV internalization (44,66,67).
Prior studies using PC3-EVs suggest that TGF-b is
tethered to the EV membrane through association with
betaglycan, a membrane-bound proteoglycan also known
as TGF-b type III receptor (68). It is possible that TGF-b
binds to its receptor on the target cell, in part mediating
EV uptake. Intriguingly, removal of EV surface sialic acid
by neuraminidase treatment showed a surprising increase
in fluorescence of RAW264.7 cells after EV internaliza-
tion, while the percentage of fluorescent cells was de-
creased (Fig. 4D). This may suggest altered intracellular
itinerary of the deglycosylated EVs after internaliza-
tion which decreased degradation of the EVs. A similar
increase in cellular fluorescence of internalized fluores-
cent-EVs following neuraminidase treatment of ovarian
cancer-derived EVs was reported in a previous study (44),
however, the percentage of fluorescent cells was not
reported in that study.
In summary, we show that PC3-EVs are capable of
inducing osteoclast differentiation and osteoblast prolif-
eration. Importantly, these effects are attenuated by cavin-
1expressioninPC3cells,consistentwiththedemonstrated
role for cavin-1 as a tumour suppressor in caveolin-1-
positive prostate cancer (19). A critical question remains
as to how cavin-1 expression selectively reduced the
EV levels of a subset of molecules that include cargo,
structural, and functional proteins and miRNA. The
common denominator may be that these molecules are
trafficked by lipid raft-dependent pathways which are
altered by cavin-1 expression (18). Further studies will
be required to delineate the molecular mechanisms and
identify potential targets to reduce the release of pro-
metastatic EVs.
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